Roche subsidiary Ventana Medical Systems will pay $100m for BioImagene on a debt-free basis.

Switzerland-based drugs company Roche has acquired BioImagene, a US-based medical device company backed by corporate venturing groups at industrial conglomerate Siemens and Ascension Health.

Roche subsidiary Ventana Medical Systems will pay $100m for BioImagene on a debt-free basis.

In October 2008, BioImagene raised its series D round for more than $26m from Siemens Venture Capital, merchant bank Burrill & Company, Ascension Health Ventures and venture capital firms Artiman Ventures, ICCP Venture Partners and National Healthcare Services.